LARGO, Fla., June 21 /PRNewswire-FirstCall/ -- GeoPharma, Inc. announced today that it will host a conference call to discuss March 31, 2007 fiscal year end earning results on Tuesday, June 26, 2007 at 11:30 (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Interested parties may participate in the conference call by dialing 1-888-713-4205 and entering passcode 70934811, 5 minutes prior to the initiation of the call. A replay of the conference call will be available from 1:30 PM (ET) on June 26 through July 3, by dialing 1-888-286-8010 and entering passcode 29615963. The Company will release earnings before trading the day of the call.
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company’s growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma’s competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com, www.hoodiadexl10.com and www.onlineihp.com .
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries’ expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company’s management as of the date hereof, and actual results may vary based upon future events, both within and without management’s control. Important factors that could cause such differences are described in the company’s periodic filings with the Securities and Exchange Commission.
GeoPharma, Inc.
CONTACT: Carol Dore-Falcone, VP & CFO, GeoPharma, +1-727-544-8866 x244,cdf@onlineihp.com; or Investor relations, Kevin Nally, of Zangani InvestorCommunity, +1-908-788-9660 x625, office@zangani.com, for GeoPharma, Inc.
